TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29441973

Group type: EXPERIMENTAL
Intervention: Angelica dahurica dressing (continuous application for 4 weeks)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Angelica dahurica dressing
Number of subjects: 98

Group type: COMPARATOR
Intervention: Compound clotrimazole cream (control)
Number of subjects: 98
Study: 24726635

Group type: EXPERIMENTAL
Intervention: Clevidipine
Number of subjects: 1410

Group type: COMPARATOR
Intervention: Control (Nitroglycerin, Sodium Nitroprusside, Nicardipine)
Number of subjects: 1410

Group type: EXPERIMENTAL
Intervention: AUC≤10 mmHg×min/h
Number of subjects: 1410
Study: 22404883

Group type: COMPARATOR
Intervention: Repeated short-term exposure to +22°C for up to three periods of 3 h on days 3, 8, and 15 of storage, followed by a 5 h exposure on day 29.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Repeated short-term exposure to -2°C for up to three periods of 3 h on days 3, 8, and 15 of storage, followed by a 5 h exposure on day 29.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exposure of RCC to 25°C for 24 h from day 2.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exposure of RCC to 25°C for 48 h from day 2.
Number of subjects: 0
Study: 19520901

Group type: EXPERIMENTAL
Intervention: Shame transformation treatment program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 18420852

Group type: EXPERIMENTAL
Intervention: Haloperidol 1 mg
Number of subjects: 244

Group type: COMPARATOR
Intervention: Ondansetron 4 mg
Number of subjects: 244
Study: 16388832

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 100 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 12728422

Group type: EXPERIMENTAL
Intervention: Medial parapatellar approach with tourniquet application
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Midvastus approach with tourniquet application
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Midvastus approach after tourniquet deflation
Number of subjects: 10
Study: 11115460

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (0.27 mmol/kg body weight) infused IV over 20 min
Number of subjects: 22

Group type: COMPARATOR
Intervention: Isotonic glucose infusion
Number of subjects: 22
Study: 8784112

Group type: EXPERIMENTAL
Intervention: Tirilazad mesylate, 6 mg/kg per day for 3 days
Number of subjects: 660

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 660
Study: 1628130

Group type: EXPERIMENTAL
Intervention: Pentaglobin (IgM and IgA enriched intravenous immunoglobulin)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Pentaglobin
Number of subjects: 63
Study: 6381968

Group type: EXPERIMENTAL
Intervention: Oestrogen/progestogen + Calcium (0.5 g daily)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo + Calcium (0.5 g daily)
Number of subjects: 17
Study: 31714324

Group type: EXPERIMENTAL
Intervention: VR (Virtual Reality)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: VR enhanced (Visual feedback overstated)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Follow-up
Number of subjects: 8

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 8
Study: 30142847

Group type: EXPERIMENTAL
Intervention: Moxibustion with behavioral training (8 to 12 sessions during the first 4 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Behavioral training only (first 4 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moxibustion
Number of subjects: 0
Study: 26210308

Group type: EXPERIMENTAL
Intervention: 3D Fluoronavigation
Number of subjects: 143

Group type: COMPARATOR
Intervention: Conventional surgical procedure (Group C)
Number of subjects: 143
Study: 24751323

Group type: EXPERIMENTAL
Intervention: Dihydrotestosterone (DHT) 70 mg daily transdermal treatment
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo gel treatment
Number of subjects: 114
Study: 22282542

Group type: EXPERIMENTAL
Intervention: Telephone counseling (self‐help materials and up to six counseling sessions)
Number of subjects: 2277

Group type: COMPARATOR
Intervention: Self‐help (self‐help materials only)
Number of subjects: 2277
Study: 20802287

Group type: EXPERIMENTAL
Intervention: Hypertrophy-intensity group (3 sets of 12 repetitions at 70% of 1RM)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Strength-intensity group (3 sets of 6 repetitions at 85% of 1RM)
Number of subjects: 16
Study: 18468013

Group type: EXPERIMENTAL
Intervention: Inhalational anesthetic regimen (group A)
Number of subjects: 784

Group type: COMPARATOR
Intervention: Non-inhalational anesthetic regimen (group B)
Number of subjects: 784
Study: 15939028

Group type: EXPERIMENTAL
Intervention: Integration approach (endogenous control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control approach (exogenous trigger)
Number of subjects: 0
Study: 12905557

Group type: EXPERIMENTAL
Intervention: Patients with acute rejection episodes
Number of subjects: 52

Group type: COMPARATOR
Intervention: Patients without acute rejection episodes
Number of subjects: 52
Study: 10568558

Group type: EXPERIMENTAL
Intervention: Pacemaker therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temporary pacing during tilt-table testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Permanent pacing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rate-drop responsiveness
Number of subjects: 0
Study: 8732120

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus systemic interleukin 2 (IL‐2)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus radiotherapy
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus radiation and IL‐2
Number of subjects: 200

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 200
Study: 1744911

Group type: EXPERIMENTAL
Intervention: Choice of coping strategies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Assigned coping strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High internal health locus of control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: External health locus of control
Number of subjects: 0
Study: 6609268

Group type: EXPERIMENTAL
Intervention: Cellulose acetate (CA) hemodialysis membranes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cuprophan (Cu) hemodialysis membranes
Number of subjects: 0
Study: 30508996

Group type: EXPERIMENTAL
Intervention: Selective saddle rhizotomy using thermal radiofrequency ablation of S3 on one side and bilateral ablation of S4 and S5 (RF group, n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional chemical rhizotomy using hyperbaric 6% phenol in glycerin (Phenol group, n = 20)
Number of subjects: 40
Study: 26795622

Group type: EXPERIMENTAL
Intervention: 0.05 % chlorhexidine digluconate (CHX)/herbal extract combination
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.1 % chlorhexidine solution
Number of subjects: 40
Study: 25515666

Group type: EXPERIMENTAL
Intervention: Stabilization surgery followed by physiotherapy rehabilitation
Number of subjects: 140

Group type: COMPARATOR
Intervention: Physiotherapy rehabilitation alone
Number of subjects: 140
Study: 22378155

Group type: EXPERIMENTAL
Intervention: Daily oral lisinopril 2.5 mg (n = 17)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Daily oral placebo (n = 16)
Number of subjects: 33
Study: 21076717

Group type: EXPERIMENTAL
Intervention: 1 mg/day folic acid supplementation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 18801859

Group type: EXPERIMENTAL
Intervention: Lower-extremity exercise and walking intervention program
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (n=38)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Both groups received diabetic foot care education and regular foot care
Number of subjects: 79
Study: 15886721

Group type: EXPERIMENTAL
Intervention: Risperidone 6 mg/day for 12 weeks
Number of subjects: 78

Group type: COMPARATOR
Intervention: Haloperidol 20 mg/day for 12 weeks
Number of subjects: 78

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 78
Study: 14989068

Group type: EXPERIMENTAL
Intervention: Dan Shao Tang (DST) and western medicine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 90
Study: 10834778

Group type: EXPERIMENTAL
Intervention: Continuous thoracic epidural analgesia with bupivacaine-fentanyl (CEA)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia with morphine sulfate (PCA)
Number of subjects: 33
Study: 9105543

Group type: EXPERIMENTAL
Intervention: Meloxicam (7.5-30 mg)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Meloxicam (various formulations)
Number of subjects: 78
Study: 8371127

Group type: EXPERIMENTAL
Intervention: Clarithromycin suspension 7.5 mg/kg bodyweight twice daily
Number of subjects: 145

Group type: COMPARATOR
Intervention: Amoxycillin suspension 125 mg (bodyweight < 25 kg) or 250 mg (bodyweight ≥ 25 kg) three times a day
Number of subjects: 145
Study: 3524488

Group type: EXPERIMENTAL
Intervention: Papaverine 60 mg added to cold cardioplegia
Number of subjects: 495

Group type: COMPARATOR
Intervention: Cold cardioplegia without papaverine
Number of subjects: 495
Study: 30709324

Group type: EXPERIMENTAL
Intervention: Synbiotic
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 29326021

Group type: EXPERIMENTAL
Intervention: Simple rTMS protocol on the left dorsolateral prefrontal cortex (lDLPFC)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Complex rTMS protocol using six regions of interest
Number of subjects: 19
Study: 26282062

Group type: EXPERIMENTAL
Intervention: Maxacalcitol topical ointment (22‐oxacalcitriol [OCT]), applied twice daily for 8 weeks
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Maxacalcitol topical ointment (22‐oxacalcitriol [OCT])
Number of subjects: 188
Study: 24256098

Group type: EXPERIMENTAL
Intervention: Supplementary transcatheter arterial embolization (STAE) performed after achieved endoscopic hemostasis
Number of subjects: 105

Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Supplementary transcatheter arterial embolization (STAE)
Number of subjects: 105
Study: 22307384

Group type: EXPERIMENTAL
Intervention: Teriflunomide 7 mg/day
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Teriflunomide 14 mg/day
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Teriflunomide (both doses)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo (initially) then switched to Teriflunomide
Number of subjects: 179
Study: 20609215

Group type: EXPERIMENTAL
Intervention: Iloprost infusion (single day or five days, eight hours)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Iloprost infusion
Number of subjects: 50

Group type: COMPARATOR
Intervention: Patients with systemic sclerosis
Number of subjects: 50

Group type: COMPARATOR
Intervention: Patients with digital ulcers
Number of subjects: 50
Study: 18048820

Group type: EXPERIMENTAL
Intervention: Oral minocycline
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Topical tazarotene
Number of subjects: 48
Study: 16211753

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg orally, twice daily for 2.5 days)
Number of subjects: 9
Study: 12106841

Group type: EXPERIMENTAL
Intervention: Doppler myocardial imaging (DMI)
Number of subjects: 5
Study: 10758656

Group type: EXPERIMENTAL
Intervention: Momordica charantia (Karolla) extracts
Number of subjects: 100
Study: 7726484

Group type: EXPERIMENTAL
Intervention: Intranasal pirodavir (2 mg per treatment) six times daily for 5 days
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Intranasal pirodavir
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 1974394

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 micrograms/kg)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 39
Study: 7343510

Group type: EXPERIMENTAL
Intervention: Structured reminiscing for forty-five minutes during each of five weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Focus on current life events (control group)
Number of subjects: 21

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 21
Study: 31665059

Group type: EXPERIMENTAL
Intervention: Remotely controlled mandibular positioner (RCMP) during polysomnography (PSG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DISE-assisted titration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional subjective titration method
Number of subjects: 0
Study: 28893675

Group type: EXPERIMENTAL
Intervention: Opioid therapy
Number of subjects: 240

Group type: COMPARATOR
Intervention: Non-opioid medication therapy
Number of subjects: 240
Study: 26496285

Group type: EXPERIMENTAL
Intervention: Scaling and Root Planing (SRP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Scaling and Root Planing (SRP) + Low-Level Laser Therapy (LLLT)
Number of subjects: 40
Study: 24612989

Group type: EXPERIMENTAL
Intervention: Counter-advertisement (animated web banner ad challenging front-of-package promotion)
Number of subjects: 1351

Group type: COMPARATOR
Intervention: Control advertisement (animated web banner ad)
Number of subjects: 1351

Group type: EXPERIMENTAL
Intervention: Counter-advertisement (misunderstood)
Number of subjects: 1351
Study: 22619096

Group type: EXPERIMENTAL
Intervention: Therapeutic massage in addition to kinesiotherapy and physiotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Kinesiotherapy and physiotherapy only
Number of subjects: 60
Study: 19590518

Group type: EXPERIMENTAL
Intervention: 1 mg intracameral triamcinolone acetonide (TA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no injection of TA)
Number of subjects: 120
Study: 16704874

Group type: EXPERIMENTAL
Intervention: <70% correction formula for mixing tests on aPTT
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Rosner index for mixing tests on aPTT
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: dPT mixing tests
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Rosner index for mixing tests on dPT
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: percent correction formula for mixing tests on dPT
Number of subjects: 361
Study: 16328318

Group type: EXPERIMENTAL
Intervention: BAY 59-7939 (5 mg, 10 mg, 20 mg, 30 mg bid)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: BAY 59-7939
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 12034031

Group type: EXPERIMENTAL
Intervention: Interferon (IFN) monotherapy
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Interferon (IFN) plus ribavirin
Number of subjects: 91
Study: 10449028

Group type: EXPERIMENTAL
Intervention: Progressive Speed Protocol (PSP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Progressive Incline Protocol (PIP)
Number of subjects: 20
Study: 7817967

Group type: EXPERIMENTAL
Intervention: 125-nmol/m3 increment in particle-strong acidity for 12 hours
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: 30-ppb increment in ozone for 12 hours
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: 125-nmol/m3 increment in particle-strong acidity for 12 hours among symptomatic children
Number of subjects: 83
Study: 2193560

Group type: COMPARATOR
Intervention: Adenosine 3 mg
Number of subjects: 359

Group type: COMPARATOR
Intervention: Adenosine 6 mg
Number of subjects: 359

Group type: COMPARATOR
Intervention: Adenosine 9 mg
Number of subjects: 359

Group type: COMPARATOR
Intervention: Adenosine 12 mg
Number of subjects: 359

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Adenosine 6 mg followed by 12 mg if necessary
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Verapamil 5 mg followed by 7.5 mg if necessary
Number of subjects: 359
Study: 6818806

Group type: EXPERIMENTAL
Intervention: 2-4 mg of micronized oestradiol-17 beta taken orally
Number of subjects: 38

Group type: COMPARATOR
Intervention: 3 mg of oestradiol-17 beta applied cutaneously
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Doubling of the oral dose from 2 mg to 4 mg
Number of subjects: 38
Study: 31813087

Group type: EXPERIMENTAL
Intervention: Apalutamide
Number of subjects: 1207
Study: 31262379

Group type: EXPERIMENTAL
Intervention: Reslizumab 3.0 mg/kg every 4 weeks for 1 year
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo every 4 weeks for 1 year
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reslizumab
Number of subjects: 0
Study: 28225996

Group type: EXPERIMENTAL
Intervention: Diacerein as an add-on to metformin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 25701295

Group type: EXPERIMENTAL
Intervention: Color-coded prefilled medication syringes
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional medication administration methods
Number of subjects: 10
Study: 24835497

Group type: EXPERIMENTAL
Intervention: Lidocaine/tetracaine patch
Number of subjects: 20

Group type: COMPARATOR
Intervention: Injectable 1% lidocaine
Number of subjects: 20
Study: 22709364

Group type: EXPERIMENTAL
Intervention: Knowledge of ocular diseases related to smoking
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Asking patients if they smoke
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Advising smoking patients to stop smoking
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Awareness of resources for smoking cessation
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Regularly asking patients about smoking status
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Advising patients to stop smoking if they smoke
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Knowledge of resources for smoking cessation
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Perceived competence in offering counselling
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Main obstacle to smoking cessation counselling
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Interest in acquiring competencies in smoking cessation counselling
Number of subjects: 288
Study: 18810388

Group type: EXPERIMENTAL
Intervention: Lacrilube
Number of subjects: 40

Group type: COMPARATOR
Intervention: Geliperm
Number of subjects: 40
Study: 19717184

Group type: EXPERIMENTAL
Intervention: Otamixaban 0.035 mg/kg/h
Number of subjects: 3241

Group type: EXPERIMENTAL
Intervention: Otamixaban 0.070 mg/kg/h
Number of subjects: 3241

Group type: EXPERIMENTAL
Intervention: Otamixaban 0.105 mg/kg/h
Number of subjects: 3241

Group type: EXPERIMENTAL
Intervention: Otamixaban 0.140 mg/kg/h
Number of subjects: 3241

Group type: EXPERIMENTAL
Intervention: Otamixaban 0.175 mg/kg/h
Number of subjects: 3241

Group type: COMPARATOR
Intervention: Control (unfractionated heparin + eptifibatide)
Number of subjects: 3241
Study: 15942583

Group type: EXPERIMENTAL
Intervention: Bivalirudin (bolus of 50 mg in priming solution, 1.0 mg/kg for the patient, followed by an infusion of 2.5 mg . kg(‐1) . h(‐1) until 15 minutes before the conclusion of cardiopulmonary bypass)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cardiotomy suction
Number of subjects: 10
Study: 12072621

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 9868121

Group type: EXPERIMENTAL
Intervention: Tinidazole
Number of subjects: 45

Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 45
Study: 8194933

Group type: EXPERIMENTAL
Intervention: Facilitator model
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Informational model
Number of subjects: 91

Group type: COMPARATOR
Intervention: Routine Treatment
Number of subjects: 91
Study: 3556133

Group type: EXPERIMENTAL
Intervention: Combination of intravenous and oral Pentoxifylline with walk training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Walk training alone
Number of subjects: 30
Study: 12036640

Group type: EXPERIMENTAL
Intervention: Intracameral cefuroxime 1 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (nonadministration of intracameral antibiotic prophylaxis)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 90
Study: 31466895

Group type: EXPERIMENTAL
Intervention: TIPS laparoscopic appendectomy
Number of subjects: 37

Group type: COMPARATOR
Intervention: Video of laparoscopic appendectomy
Number of subjects: 37
Study: 30312309

Group type: EXPERIMENTAL
Intervention: Health post (HP) based intervention arm
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Health center (HC) based intervention arm
Number of subjects: 282

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 282
Study: 27504403

Group type: EXPERIMENTAL
Intervention: K-Loop molar distalization
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pendulum appliance
Number of subjects: 30
Study: 24560365

Group type: EXPERIMENTAL
Intervention: Moxidectin (MOX) at 0.2mg/kg bodyweight
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Ivermectin (IVM) at 0.2mg/kg bodyweight
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Levamisole (LEV) at 7.5mg/kg bodyweight
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Benzimidazole (BZ) at 3.75-5mg/kg bodyweight
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Netobimin (NET) at 7.5mg/kg bodyweight
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Multi-drug resistance (MDR) identified
Number of subjects: 500
Study: 22366293

Group type: EXPERIMENTAL
Intervention: Insulin regimen A
Number of subjects: 67

Group type: COMPARATOR
Intervention: Insulin regimen B
Number of subjects: 67
Study: 20369095

Group type: EXPERIMENTAL
Intervention: Group 1 (bar) - splinted mini-implants inserted using a prefabricated stainless steel guide
Number of subjects: 45

Group type: COMPARATOR
Intervention: Group 2 (ball) - splinted mini-implants placed without a guide
Number of subjects: 45
Study: 18380825

Group type: EXPERIMENTAL
Intervention: 10 mg of i.v. furosemide
Number of subjects: 62

Group type: COMPARATOR
Intervention: Oral fluids only (control)
Number of subjects: 62
Study: 16280073

Group type: EXPERIMENTAL
Intervention: Menopur (subcutaneous, SC)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Repronex (subcutaneous, SC)
Number of subjects: 125
Study: 12371576

Group type: EXPERIMENTAL
Intervention: Family Empowerment Intervention (FEI) - three one-hour, home-based meetings per week for approximately 10 weeks from a clinician-trained paraprofessional.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Extended Services Intervention (ESI) - monthly phone contacts and referral information as needed.
Number of subjects: 0